Clinical and Therapeutic Predictors of Disease Outcomes in AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder

This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research